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At  present  multiple  sclerosis  (MS) 1 presents  a  very  complex  medical  problem. 
There are three fundamental reasons for this: first, the diagnosis of MS is extremely 
difficult (1) ; secondly, the etiology of the disease is unknown (2) ; and finally, a problem 
that is the keystone to  the analysis of the  other problems is the lack of a  system, 
other  than  man,  in  which  the  disease can  be  studied.  In  experiments initiated to 
investigate the  etiology of MS, Palsson et al.  (3)  and  Field (4)  described a  disease 
in sheep and mice, respectively, that had been inoculated with MS brain homogenate. 
In  each  instance  the  disease was  characterized by  spongiform  degeneration of  the 
central nervous system (CNS). The significance of these findings is difficult to assess 
because: (a) these results have not been confirmed by others despite several attempts, 
and (b) it is not possible to exclude the possibility of contamination of the MS brain 
material or the test animals with scrapie, an agent with known potential for causing 
spongiform degeneration in these animals (5). 
An  important  limitation of  the  above  studies  was  the  fact  that  the  only 
criteria for infection were  clinical signs and/or histopathological changes. We 
have  been  searching for  less overt  alterations  at  the  cellular and  subcellular 
level after inoculation with MS material. The results reported here describe an 
alteration in the per cent polymorphonuclear neutrophils (PMN)  in clinically 
normal mice after inoculation with material from MS patients. 
Materials and Methods 
Specimen  Sources.--All  specimens  were  kindly supplied by Dr.  W.  W. Tourtellotte of 
Wadsworth General Hospital, Los Angeles, Calif.  This material came from  cases that had 
been clinically diagnosed  and  histopathologically confirmed  as MS.  The sample materials 
included  brain,  spleen,  eerebrospinal fluid  (CSF),  and  serum.  Each  sample came from  a 
different  MS case. Normal controls were tissues  and fluids obtained from  individuals with 
no history of CNS disease. 
*This work was supported in part by grant No.  723-A-1 from the National Multiple 
Sclerosis Society. 
1 Abbreviations used in this paper: CNS, central nervous system; CSF, cerebrospinal fluid; 
EE,  Eagle's medium  in Earle's balanced salt solution; MS,  multiple sclerosis; ]?MN, poly- 
morphonuclear  neutrophils; RBC, red blood cells. 
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Preparation  of Solid Tissue Material.--Brain and spleen sections were minced, made up 
to a  20%  (w/v)  suspension in Eagle's medium in Earle's balanced salt solution  (EE)  con- 
taining penicillin (100 units/ml) and streptomycin (100 #g/ml), and homogenized in a  Ten- 
Broek tissue grinder  (Fisher  Scientific Co.,  Springfield, N.  J.) using 20 strokes  per sample. 
The homogenate was then centrifuged for  15  min  at  1500  g and the supernatant removed 
and frozen. The remaining pellet was frozen and thawed three times and resuspended to the 
original volume, then centrifuged as before. The two  supernatants were  pooled  and  stored 
at  -20°C until needed.  Samples were tested for sterility before use. 
Brain Pools Used  for Inoculation.--Coronal sections from two normal human brains were 
prepared as above, pooled, and used as the normal human brain homogenate unless other- 
wise specified.  Coronal sections having pathological lesions from three different MS  brains 
were prepared  as  above  and  pooled.  This  comprised  the  MS  brain homogenate inoculum 
unless otherwise specified. 
Mouse Inoculations.--Male,  weanling C57BL/6J  mice were  inoculated  either intraperi- 
toneally with 0.2 ml of material or intracerebrally with 0.03 ml. 
Total Leukocyte Counts.--Total leukocyte counts were done by mixing a  20 #1 sample of 
freshly drawn blood with "ZAP" (Coulter Electronics, Hialeah, Fla.), a red blood cell (RBC) 
lysing agent, in 10 ml of physiological saline. The number of leukocytes was determined with a 
Coulter electronic cell counter,  Model B  (Coulter  Electronics).  Settings were  12.5  for  the 
lower and 100 for the upper thresholds. Amplification was set at ~  while the aperture current 
was at ~.  The resultant count was equal to the number of leukocytes per cubic millimeter 
of whole blood. 
Differential  Leukocyte  Counts  and  Stainlng.--Peripheral  blood  smears were  made  using 
heparinized blood  obtained from  the brachial artery and vein of  ether-anesthetized mice. 
Mter 24 hr, smears were stained by flooding the slides with Wright's staining solution for 
7 rain. Then a few drops of Giordano's buffer (pH 6.5)  were added for an additional 6 rain. 
The slides were rinsed with distilled water and air-dried. All slides were coded such that the 
experimenter did not know the origin of the material. The slides were read under oil immer- 
sion (X  1250) for the distribution of white blood cell types. 
Filtration  of MS Brain MateriaL--Extracts  of MS brain material were passed through a 
series of membrane filters (Millipore Corp., Bedford, Mass.) of decreasing size (220,  100, 50, 
25 nm). The filtrates at each stage were inoculated intracerebrally into groups of mice. 
RESULTS 
Altered Leukocyte Distributions  in MS-Inoculated  Mice.--Differential leuko- 
cyte  counts  were  performed  on  mice  after  intraperitoneal  or  intracerebral 
inoculation  of  brain  homogenate  prepared  from  normal  individuals  or  MS 
patients.  Three mice from each group were tested  every 2  or 3  wk for 43 wk 
after intraperitoneal and 37 wk after intracerebral inoculation. At 2  and 4  wk 
after inoculation, mice inoculated with MS material showed an altered distribu- 
tion of leukocyte cell  types which was characterized by a  decrease in  the per 
cent PMN with a concomitant increase in the per cent lymphocytes. In Fig.  1, 
the average  (three mice/point)  PMN  percentages  are expressed  as a  function 
of  time  after  inoculation.  The  lower percentages  of  PMN  in  MS-inoculated 
mice were manifest  throughout the  entire period  of  the  experiment  for both 
intracerebral and intraperitoneal mice. Although most of the PMN values for 
MS mice were lower than normal,  a  few  (7.5%)  had values  that were higher 
than those found for mice inoculated with normal brain homogenate (see a  in 620  PMN  DECREASES  IN  MS-INOCULATED MICE 
Fig.  1). It is not clear whether these few high values bear any relation to the 
inoculation of MS material. For intracerebraily inoculated mice, the difference 
in  PMN  percentages between normal  and  MS  groups  were statistically  sig- 
nificant (P of no difference --<0.05 by the Mann-Whitney U  test)  at all times 
except at 18 and 32 wk after inoculation. For intraperitoneal inoculation, the 
differences were also statistically significant (_-<  0.05) except at 2 wk and at those 
points marked a.  To further evaluate the results,  all of the individual PMN 
values in each treatment group were pooled across the entire time period. When 
arranged as frequency distributions the PMN percentages obtained among the 
four groups showed virtually no overlapping (Fig. 2). Almost all values for MS 
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FIO.  1.  Average per cent PMN in mice as a function of time after inoculation with MS 
brain homogenate (•), or normal human brain homogenate (©); intracerebrally inoculated, 
A;  intraperitoneally inoculated,  B.  (a)One  value  that  was  markedly  different from  the 
usual value for normal or MS-inoculated mice. This value was not included in the average 
for that particular point. 
mice were lower than  those for normal mice, and  the few exceptional values 
noted above were higher than most normal values. 
As  additional  controls, we performed differential leukocyte counts  on  the 
peripheral  blood of mice in  the  following groups:  (a)  uninoculated  and  (b) 
inoculated with EE, the diluent used for the preparation of brain homogenates. 
These mice were tested at ages comparable to those used for the above studies. 
The average percentage of each leukocyte type was computed for each of the 
six treatment groups (Table I). Those values marked with a in Fig. 1 were not 
included in the summary. The values obtained for mice inoculated with EE or 
normal human brain and for uninoculated mice are similar to those that have 
been described for C57BL/6J mice (6). The differences in the average PMN (or 
lymphocyte) percentages between MS mice and any control group were highly 
statistically  significant  (Student's  t  test,  P  ~  0.001).  All  other  comparisons 
failed to reveal any statistically significant differences. R.  I.  CARP,  P.  C.  LICURSI~ P.  A.  MERZ~ G.  S.  MERZ  621 
Cell  Type Responsible for the Alteration in Leukocyte Differential  Counts.-- 
From observations of the blood cell smears it was obvious that the alteration in 
the  distribution of  the  leukocyte  cell  types  after  MS  inoculation cannot be 
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FIG. 2.  Distribution of  per cent PMN  among mice inoculated with  A,  normal human 
brain, and B, MS brain inoculated intracerebrally; C, normal human brain, and D, MS brain 
inoculated intraperitoneally. 
TABLE I 
Per Cent Leukocyte Types in MS-Inoculated and Control C57BL/6J .~ice 
Leukocyte distribution* 
No.  Polynlorph-  Inoculum  and route  tested  onuclear  Lymphocytes Eosinophils  Monocytes 
neutrophils 
None  36  13.4(2.9)  85.6(3.1)  0.8(1.2)  0.2(0.4) 
Eagle's medium (i.c.)  18  15.0(3.2)  83.9(3.5)  0.9(1.2)  0.1(0.3) 
Normal human brain (i.c.)  73  13.95(2.9)  84.9§(3.4)  0.9(1.5)  0.2(0.5) 
MS brain (i.c.)  72  5.9*(2.2)  93.1§(2.7)  0.6(0.9)  0.1(0.4) 
Normal human brain (i.p.)  58  14.61](2.8 )  83.9¶(3.5)  1.1(1.6)  0.4(1.0) 
MS brain (i.p.)  49  6.011(2.5 )  92.9¶(3.2)  0.8(1.3)  0.2(0.6) 
* Average; (SB). 
* t  =  18.54, P  of no difference  <<0.001. 
§ t  --  16.09, P  of no difference  <<0.001. 
I] t  ~  16.60, P  of no difference ~<0.001. 
¶ t =  13.88, P  of no difference <<0.001. 
accounted for by the appearance of unusual or abnormal cell types, e.g., atypical 
lymphocytes or juvenile PMN.  Rather,  the change in differential counts repre- 
sents  an altered  distribution of normal cell  types.  Secondly,  the  alteration  in 
differential counts cannot be accounted for by increases in either eosinophils or 622  PMN  DECREASES  IN  MS-INOCULATED  MICE 
monocytes,  since  they occur at very low frequencies in  all  of  the  treatment 
groups. The third and fourth possibilities are that either there is an increase in 
the number of lymphocytes or a decrease in the number of PMN. These alterna- 
tives can be distinguished by their effect on total leukocyte counts. A decrease 
in the percentage of PMN from 14.0  per cent noted in normal mice to 5.5  per 
cent noted in MS  mice would  require  an increase in  the  absolute number of 
lymphocytes of approximately threefold. This, in turn,  would cause a  2.5-fold 
increase in the total leukocyte counts. In contrast,  a  decrease in  the absolute 
number of PMN would hardly affect the total leukocyte count. To test these 
alternate  possibilities,  total  leukocyte  counts  and  per  cent  PMN  were  de- 
termined on each of 19 MS-inoculated mice as well as on 29 control mice (inocu- 
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Fro.  3.  Total leukocyte count plotted against the percentage of PMN.  Normal mouse or 
human, o, MS, m. 
lated with normal human or normal mouse brain). The results (arranged as a 
scatter diagram in Fig. 3) show that: (a) there is no obvious association between 
high total leukocyte counts and low PMN percentages;  and  (b)  the  range in 
total leukocyte counts is approximately the  same for MS- and normal brain- 
inoculated mice. These conclusions are supported by statistical analysis in that 
(a) the correlation coefficient r for MS mice is 0.001  and that for normal mice is 
0.008,  and (b) the mean total leukoc)te counts among the MS-inoculated  mice 
is not statistically different from that of normal mice (Student's t test). There- 
fore, the  altered leukocyte distribution  in MS-inoculated  mice is caused by a 
decrease in the absolute number of PMN. 
Early Appearance of the Decrease in PMN Percentages.--To determine how 
soon after inoculation the PMN percentages changed differential counts were 
performed early after intracerebral  inoculation with  MS material  (Table II). 
The per cent PMN at 4 and 8 hr postinoculation were higher than the values in 
normal human brain-inoculated mice. The significance of these data is not clear, R.  I.  CARP, P.  C.  LICURSI, P.  A.  MERZ, G.  S.  MERZ  623 
but they may represent a response to the inoculation  per se. From 16 hr onward, 
however, the decrease in per cent PMN in mice was well established  and sta- 
tistically significant. After intraperitoneal inoculation (Table III), the decrease 
TABLE II 
Effect of MS and Normal Brain Homogenate  on the Per Cent PMN  As a  Function of Time 
after [ntracerebral  Inoculation 
Time postinoculation 
Average* of PMN percentages 
Normal  MS 
4 hr  85  21 
8 hr  9~  18 
12 hr  13  11 
16 hr  15  5~ 
20 hr  16  8~ 
24 hr  14  65 
26 hr  13  5~ 
48 hr  14  6~ 
52 hr  11  7~ 
3 days  11  4~ 
4 days  12  6~ 
5 days  18  8~ 
10 days  12  6~ 
* Average of three animals. 
:~ P of no difference < 0.05 (Mann-Whitney U test). 
TABLE III 
Effect of MS and Normal Brain Homogenate  on the Per Cent PMN  As a Function of Time 
after Intraperitoneal Inoculation 
Time postinoculatlon 
Average* of PM2q percentages 
Normal  MS 
12 hr  9  8 
24 hr  10  9 
48 hr  12  7, 
3 days  13  9, 
4 days  12  7, 
5 days  15  5, 
7 days  16  6, 
14 days  12  7~ 
* Average of three animals. 
:~ P of no difference <  0.05 (Mann-Whitney U test). 
in per cent PMN was apparent 48 hr postinoculation  and the difference remained 
statistically significant during the rest of the experiment. 
Titration  of the PMN  Factor.--To  quantitate the amount of factor causing 
the decreased PMN that was present in the MS brain homogenate, mice were 
inoculated intracerebrally with decimal dilutions (in EE)  of the homogenate. 624  PMN  DECREASES IN MS-INOCULATED  MICE 
Differential leukocyte counts were done 3, 4, 5, and 9 wk after inoculation. The 
results  are summarized  in Table IV. The highest  dilution that  still  caused  the 
decreased PMN percentage was 10  -n. This would correspond to a  titer of 3  X 
1012/ml  in  the  original homogenate.  During  the interval  between  3  and  4  wk 
postinoculation there was a  100-fold increase in the highest dilution causing the 
PMN decrease (10-9-10-n), with no further change noted during the subsequent 
5 wk of the experiment. 
Occurrence of the Factor in the Blood  of MS-Inoculated  Mice.--It is apparent 
from Fig. 1 that the decrease in PMN persists for many months after inocula- 
tion. To determine whether the factor responsible for the decrease was likewise 
TABLE IV 
Percentages of PMN in Mice Inoculated Intracerebrally with Dilutions of MS Brain Homogenate 
3 wk  4 wk  5 wk  9 wk  Dilution  % PMN (avg)  % PMN (avg)  % PMN (avg)  % PMN (avg) 
lO--t 
10-2 
10-a 
10-4 
10-~ 
10-6 
10--7 
10-8 
10-9 
10-1o 
10--11 
10--12 
lO-t~ 
10--14 
10-1~ 
6,  4,  8,  9  (6.8) 
7,  6,  8,  7  (7.0) 
7,  10,  6,  8  (7.8) 
7,  7,  6,  9  (7.3) 
4,  7,  5,  S  (6.0) 
7,  5,  5,  2  (4.8) 
8,  9,4,5  (6.5) 
7,  6,  3,  8  (6.0) 
8,  10,  8  (8.7) 
14,  13  (13.5)  5,  4  (4.5) 
5,  7  (6.0) 
10,  11  (10.5.) 
5,  7  (6.0) 
13,  13  (13.0) 
13,  12  (12.5)  13,  12  (12.5) 
12,  12  (12.0)  13,  14  (13.5) 
12,  13  (12.5)  12,  12  (12.0) 
present  for long periods,  we inoculated  mice with  serum  obtained  from mice 
that  had  been  inoculated  with  MS  brain  homogenate.  The  protocol  was  as 
follows: (a) Donor mice were inoculated intracerebrally with MS brain homog- 
enate.  (b)  At 12 hr, 4  and 29 wk, groups of donor mice were killed,  serum col- 
lected,  and  differential  leukocyte  counts  performed.  (c)  The  sera  were  then 
inoculated into recipient mice. (d) At 3 and 5 wk, differential  leukocyte counts 
were  done  on  recipient  mice.  (e)  The  results  were  compared  with  similarly 
treated mice in which the donor mice had been inoculated with normal human 
brain  homogenate.  In  addition,  differential  leukocyte counts  were  performed 
and serum collected from mice that had been inoculated intraperitoneally 34 wk 
earlier with MS brain homogenate. This serum along with that from its normal 
human brain-inoculated  controls was inoculated intracerebrally into a group of 
recipient mice which were then treated as above in d. The results of the experi- 
ment  (Table  V)  show that  all  of the  MS-inoculated  donor mice exhibited  the R.  I.  CARP,  P.  C.  LICURSI,  P.  A.  MERZ,  G.  S.  ]~[ERZ  625 
decreased  per  cent  PMN  except  those  examined  12  hr  after  intracerebral 
inoculation  and  that  all of  the  recipient mice  showed  a  decrease in  per  cent 
PMN,  including those inoculated with the serum taken from donor mice only 
12 hr after inoculation. Thus,  the factor responsible for the decreased per cent 
PMN  was present and detectable in the serum of donor mice from as early as 
12  hr until at least as late as 8 1/~ months postinoculation. These results also 
show that the factor present in the MS tissue can be transmitted from mouse to 
mouse. 
Replication of the PMN  Factor in Mice.--To determine if the  PMN  factor 
can  replicate in  the mouse  the following experiment was performed.  The  MS 
brain  homogenate  was  diluted  to  10.  9 and  inoculated  into  four  mice  (intra- 
cerebrally). Based on the titer noted in Table IV, mice inoculated with a  10. o 
TABLE V 
Per  Cent PMN in  Mice  (Recipient) Inoculated with Serum from  Mice  (Donor) Inoculated 
with MS Brain Homogenate 
Recipient inocula:  % PMN in donor mice 
Donor sera collected  at  (at time of serum 
collection)  the following times 
after MS inoculation:*  MS  Normal 
% PMN  in recipient mice at 
3 wk  5 wk 
MS  Normal  MS  Normal 
12 hr  11~  13  6§  16  8§  12.5 
4 wk  8  17  9  19.5  4  13 
29 wk  6  13  13.5  26  7.5  12.5 
34 wk  6  15  6  14  6  12.5 
* Donor mice from  12 hr, 4 wk, and 29 wk had been inoculated i.c.; donor mice from 34 
wk had been inoculated i.p. 
:~ For donor mice, number  =  average of three mice. 
§ For recipient mice, number =  average of two mice. 
dilution of MS brain homogenate should have received 100 units of PMN factor. 
Two of these mice were negative for the PMN  decrease at 3 wk, but the other 
two mice were positive at 6  wk (average PMN  percentage was 6  for MS mice 
and 14.5 for the normal brain control mice). The brains of the 6-wk mice were 
homogenized and titrated, with each dilution inoculated intracerebrally into a 
new  set  of  four  mice.  Control  mice  were  inoculated  with  the  mouse  brain 
homogenate  prepared  from  mice  inoculated  with  normal  human  brain.  Dif- 
ferential leukocyte counts were performed on mice 6  wk after inoculation. All 
mice  inoculated with  dilutions  of mouse  brain  homogenate,  which  had  been 
derived from mice inoculated with  MS  material, were positive for  the  PMN 
decrease up to and including the 10  .9 dilution. Mice receiving dilutions beyond 
10  .9  and  mice  inoculated with  material  derived  from  normal  human  brain- 
inoculated mice had PMN  percentages in the normal range. The quantitative 
aspects of this experiment are shown in Table VI. The results show that there 
was an increase of the PMN  factor in mouse brain of at least 1.5  X  109-fold. 626  PMN  DECREASES IN  MS-INOCULATED MICE 
The mice at the end point (t0  -9) had received a  dilution of the original human 
brain material equivalent to 10  -~°. 
Effect of Filtration of MS Brain Material on the Per Cent PMN  in Inoculated 
Mice.--MS  brain  homogenate  was  filtered  as  described  in  Materials  and 
Methods.  Differential leukocyte counts  were performed  at  2  and  4  wk  post- 
inoculation and the pooled values are shown in Table VII. The results show that 
the factor causing the PMN decrease passed through all pore sizes except 25 nm. 
, Occurrence of the Factor Causing the Decrease in PMN  Percentages in  Various 
Tissues from Nine MS  Cases.--The  results of  a  preliminary study  of the  OC- 
TABLE VI 
Replication of the PMN Factor In Vivo 
3 N  1012/ml 
100 
100 
1.5 X  10 ll 
Titer of factor in MS brain homogenate: 
Amount of factor inoculated i.c. via 0.03 ml of a  10  -9  dilution: 
Maximum amount of factor possible in brain if there were no increase: 
Titer of factor in brain of recipient mice (end point =  10  -9, 0.03 ml 
i.c.) : 
Therefore,  net increase:  1.5 M 109-fold 
TABLE VII 
Per Cent PMN in Mice Inoculated with Filtrates of MS Brain Homogenates 
Pore size  % PMN/mouse  Average 
Unfiltered  6,  6,  6,  5,  6  5.8" 
220nm  7,  8,  7,  7,  6,  5  6.6* 
100nm  5,  8,  10,  8,  4,  8  7.1" 
50nm  8,  9,  9,  8,  6,  6  7.6* 
25 nm  26,  19,  20,  14,  16,  15  18.3 
* P  of no difference from 25 nm filtrates <0.01 (Student's t test). 
currence of the factor causing the PMN  decrease in mice in different tissues ob- 
tained from nine MS cases are summarized in Table VIII. Samples of three brain 
preparations, one  spleen preparation,  two  CSF,  and  three sera from nine dif- 
ferent cases of MS were inoculated into mice.  Control samples of two brains, 
one spleen,  two  CSF, and two  sera from seven different normal humans  were 
also inoculated into mice. All MS samples induced the decreased per cent PMN 
in 6  wk,  whereas the mice inoculated with the  control material all had  PMN 
percentages in  the  normal  range  (Table VIII).  The  average  PMN  values  of 
MS-inoculated mice when compared with the average values for mice inoculated 
with  the corresponding normal tissue were significantly different (P of no dif- 
ference _~0.05  by Student's l  test). 
DISCUSSION 
Three properties of the factor causing the PMN decrease in mice suggest that 
it is a virus: it is transmissible from mouse to mouse, it has capacity for replica- R.  I.  CA1LP~ P.  C.  LICURSI~ P.  A.  MERZ, G.  S.  MERZ  627 
tion, and its size is 25-50 nm. As a  virus it has several unusual characteristics. 
The factor was present as early as 12 hr after inoculation and was still recover- 
able from the blood 81/~ months later. The only change thus far associated with 
it is the  decrease in  PMN  percentage.  To  this date,  there  are no  clinical or 
histopathological  signs  of  disease  in  any  of  the  MS-inoculated  mice.  The 
absence of clinical disease despite the presence of virus for a  long time is not 
unique,  since similar findings have been noted, for example, with lymphocytic 
choriomeningitis virus (7) and lactic dehydrogenase virus (8). 
TABLE VIII 
.percentage of PMN in Mice fnoculated with Normal Human and MS Tissues 
Patient  Tissue  % PMN/mouse  Average  Statistical 
identification  significance* 
N-1  Normalbrain  16,  15,  14,  13,  13,  14  14.1 
N-2  Normalbrain  20,  16,  17,  14,  15,  14  14.3 
MS-1  MS brain  9,  8,  10,  8,  5,  8  8.0 
MS-2  MS brain  5,  6,  6,  8,  8,  7  6.6 
MS-3  MS brain  6,  10,  10,  5,  9,  6  7.6 
N-3  Normal spleen  12,  14,  19,  15,  16  15.2 
MS-4  MS spleen  10,  7,  6,  8,  8,  6  7.5 
N-4  Normal sera  21,  16,  11,  13  15.2 
N-5  Normal sera  22,  19,  i0,  15  16.5 
MS-5  MS sera  7,  9,  7,  3  6.5 
MS-6  MS sera  6,  3,  8,  3  5.0 
MS-7  MS sera  4,  7,  9  6.6 
N-6  Normal CSF  12,  19,  14,  10,  11  13.2 
N-7  Normal CSF  12,  13,  14,  11,  12  12.5 
MS-8  MS CSF  9,  6,  13,  3,  9  8.0 
MS-9  MSCSF  7,  11,  8,  5,  7  7.6 
P  <  0.001 
P  <  0.01 
.P <0.02 
.P <  0.05 
* .P  =  probability of no difference (Student's t test). The P  given for each kind of tissue 
is the highest value obtained after comparing each normal (N) with each MS tissue. 
The "titer" of the factor in the original human brain homogenate was 3  X  1012 
units/ml  of  a  10%  homogenate.  Such  high  titers  are unusual  among  animal 
viruses but  a  number  of comparable  titers have  been  reported. The  particle 
concentration in the blood of serum hepatitis patients can be as high as 1013/ml 
(9); plasma of chickens with avian myeloblastosis virus has been shown to con- 
tain up to 1012 particles/ml (10). In both of these instances the concentrations 
are  in  particles per  milliliter based  on  electron  microscope  observations.  In 
addition, very high LDs0 titers have been reported for both Semliki Forest and 
Bunyamwera viruses, fiters of 1012 and 10 n, respectively (11). 
As yet,  the  question of  the relationship between  the factor and  MS  is un- 
answered. The cause of the PMN  change in mice may very well be unrelated 628  PMN  DECREASES  IN  MS-INOCULATED  MICE 
to the etiology of MS in man. Changes in the proportions of leukocyte cell types 
have not been described in  clinical studies  of MS.  Certain  aspects of MS  are 
consistent  with  the  concept  of  a  "slow  infectious  disease"  as  advanced  by 
Sigurdsson  (12).  Furthermore,  similarities  have been  described  between  MS 
and scrapie,  a  known  "slow infection" of the  CNS  of lower animals  (13,  14). 
In transmission  studies  a  disease was induced  by inoculation  of MS material 
into sheep and mice that was very similar to scrapie (3, 4). These results are of 
questionable significance, since they have never been repeated. It is interesting, 
however,  that  the decrease in  PMN  noted in  MS-inoculated  mice is  also ob- 
served in mice inoculated with scrapie and that the characteristics of the MS 
and  scrapie  factors  that  induce  the  decreases  are  similar  but  not  identical 
(P. Licursi, G. S. Merz, P. A. Merz, and R. I. Carp, unpublished observations). 
Regardless of whether  or not  the  PMN  factor is related  to  the  etiology of 
MS, the findings in this report suggest that the decrease in PMN percentages 
in  mice inoculated  with  MS  material  might  serve  as  a  diagnostic  aid.  It is 
important to note that every MS sample (nine samples from nine cases) caused 
the decrease in PMN percentages, whereas none of the normal samples (seven 
samples  from  seven  individuals)  affected  the  percentage  of  PMN.  On  the 
strength  of  these  results,  further  testing  of  samples  from  MS  patients  and 
normals is underway to establish more firmly the correlation between the PMN 
decrease in mice and the presence of MS disease in man. It is of interest that 
material  as  easy  to  obtain  as  serum  (three  samples)  caused  the  decrease  in 
PMN percentages. 
SUMMARY 
Mice inoculated with brain homogenates from multiple sclerosis (MS)  cases 
showed marked changes in their leukocyte differential counts, with a decrease 
in  per  cent  polymorphonuclear  neutrophils  (PMN)  and  an  increase  in  the 
per cent l:yanphocytes. These changes were based upon an absolute decrease in 
the  number of circulating  PMN.  The decrease in  PMN  percentages was  ap- 
parent at 16 hr after infection and persisted for at least 11 months. The factor 
responsible for the  decrease in  PMN  was  (a)  recoverable from 12  hr  to  81/~ 
months after inoculation,  (b) present in human brain homogenate at a  concen- 
tration of 3  X  1012~ and (c) between 25 and 50 nm in diameter. Inoculation of 
100 units of factor into mice and subsequent  titration  showed that the factor 
had  undergone  a  net  increase  in  the  mouse  of  at  least  109-fold.  The  factor 
causing the PMN decrease was found in all MS material thus far tested: three 
brains,  one  spleen,  three  sera,  and  two  cerebrospinal  fluid  (CSF)  from nine 
cases of MS. The factor was not found in normal human material that included 
two brains, one spleen, two sera, and two CSF. 
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